There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT – Research Report) and Biophytis (BPTS – Research Report) with bullish sentiments.
Altimmune (ALT)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune today and set a price target of $25.00. The company’s shares closed last Friday at $11.26.
According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Altimmune with a $21.00 average price target, representing a 79.8% upside. In a report issued on June 24, B.Riley Financial also reiterated a Buy rating on the stock with a $21.00 price target.
See the top stocks recommended by analysts >>
Biophytis (BPTS)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biophytis, with a price target of $15.00. The company’s shares closed last Friday at $1.09, close to its 52-week low of $0.93.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Biophytis has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALT:
